Dynavax Technologies Corp
Change company Symbol lookup
Select an option...
DVAX Dynavax Technologies Corp
APTO Aptose Biosciences Inc
JNJ Johnson & Johnson
AVGO Broadcom Inc
GILD Gilead Sciences Inc
LLY Eli Lilly and Co
ABBV Abbvie Inc
CIEN Ciena Corp
TEAM Atlassian Corp
MRO Marathon Oil Corp
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.

Price
Delayed
$11.49
Day's Change
-0.045 (-0.39%)
Bid
--
Ask
--
B/A Size
--
Day's High
11.68
Day's Low
11.31
Volume
(Light)

Today's volume of 400,164 shares is on pace to be much lighter than DVAX's 10-day average volume of 2,022,387 shares.

400,164

Company Profile

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.

Valuation Ratios

Price/Earnings (TTM)
5.75x
Price/Sales (TTM)
2.01x
Price/Book (MRQ)
2.94x
Price/Cash Flow (TTM)
4.47x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

November 2022
Current Month
15.7M
Previous Month
14.4M
Percent of Float
12.36%
Days to Cover
7.5308 Days

Share Information

DVAX is in a share class of common stock
Float
127.2M
Shares Outstanding
127.6M
Institutions Holding Shares
305
86.58%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Scott D. Myers
  • David F. NovackCo-Pres.
  • Ryan SpencerCEO
  • Kelly MacDonaldCFO
  • Robert JanssenSr.VP

Address

Insider Trading

During the most recent quarter, 3M shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.